Taken together, these findings demonstrate that Fulvestrant exerts its antitumor effects by targeting M2‐like macrophages and suppressing TGF‐β and VEGF signaling, thereby remodeling the immunosuppressive tumor microenvironment and promoting CD8+ T cell infiltration. The gene discussed is TGFB1; the disease is neoplasm.